Aquatic Capital Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Aquatic Capital Management’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.76M	Buy	118,000 +15,636	+15%	+$217K	0.06%	404
2026 Q1	$1.5M	Buy	+102,364	New	+$1.63M	0.04%	456
2025 Q4	–	Sell	-55	Closed	-$405	–	1457
2025 Q3	$405	Buy	+55	New	+$281	﹤0.01%	1344

Other funds holding CRVS

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ASP

Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Aquatic Capital Management's CRVS Position: Q2 2026 in Review

Aquatic Capital Management increased its Corvus Pharmaceuticals (CRVS) stake by 15% in Q2 2026, buying an estimated $217K and bringing the position to 118,000 shares worth $1.76M. The position accounts for 0.06% of the portfolio, ranked #404.

Aquatic Capital Management first reported a position in CRVS in Q3 2025 and has held it in 3 quarters since. 173 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

Aquatic Capital Management held 118,000 shares of Corvus Pharmaceuticals worth $1.76M as of Q2 2026.
Aquatic Capital Management bought 15,636 Corvus Pharmaceuticals shares in Q2 2026, an estimated $217K.
Corvus Pharmaceuticals made up 0.06% of Aquatic Capital Management's portfolio in Q2 2026, its #404 holding.
Aquatic Capital Management first reported a position in Corvus Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
173 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Aquatic Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.